Propanc Biopharma, Inc. — Form 10-Q Summary
Business context and reporting period. This unaudited filing covers the three months ended September 30, 2021, Propanc’s first fiscal quarter of FY2022. The clinical-stage biotech is developing PRP, a preclinical pro-enzyme cancer treatment candidate; it reported no product revenue. Unless otherwise noted, amounts are in U.S. dollars.
Financial performance and position
- Revenue and margins: Revenue was $0, unchanged from the prior-year quarter. Gross margin is not meaningful because there were no sales.
- Expenses and loss: Operating expenses were $486,030, up from $383,161. Administration expense rose to $431,740 from $323,111; R&D declined to $46,554 from $50,846. Operating loss was $486,030 versus $383,161. Net loss was $490,658 versus $425,545; a $114,844 deemed dividend brought net loss available to common stockholders to $605,502. Basic and diluted loss per share was $0.02, compared with $0.71, as weighted-average shares increased to 27.1 million from 597,314.
- Other income and expense: Interest expense fell to $109,853 from $159,281. A $109,129 foreign-currency transaction gain and a $3,904 derivative fair-value loss contributed to net other expense of $4,628. The prior-year quarter had a $64,952 derivative gain and a $49,985 debt-extinguishment gain.
- Cash flow: Operating cash use was $486,758, compared with $179,949 in the prior-year quarter. Financing provided $435,000: $275,000 from warrant exercises and $160,000 of convertible-note proceeds. A positive $95,320 exchange-rate effect resulted in a $43,562 net cash increase. Ending cash was $45,817, versus $2,255 at June 30, 2021.
- Liquidity and debt: Current assets were $56,408 and current liabilities were $2,368,795, producing a $2,312,387 working-capital deficit. Total liabilities were $2,368,795; convertible notes and related accrued interest, net, were $584,608. Stockholders’ deficit was $2,306,630, and accumulated deficit was $58,804,968.
Material changes versus the prior comparable period
- Operating cash use increased by about $307,000, while net loss increased by about $65,000. The filing attributes the loss movement to changes in operating costs and other income and expense items.
- Administration expense increased by about $109,000, primarily due to higher stock-based expense for services; lower accounting and employee remuneration costs partly offset the increase.
- Common shares issued and outstanding rose from 14,055,393 at June 30 to 43,841,644 at September 30. During the quarter, the company issued 9,445,009 shares for debt conversions and substantial additional shares for services and accrued compensation.
- Cash increased from the June 30 balance, supported by warrant exercises and new convertible-note financing, but remained very low relative to current liabilities.
Outlook, risks, contingencies and unusual items
- Going concern: Management said the company did not have sufficient available cash to meet obligations over the next 12 months. The filing states that substantial doubt exists about the company’s ability to continue as a going concern. Continued operations depend on raising additional capital; there is no assurance financing will be available on acceptable terms.
- Debt defaults: At September 30, the company was in default on certain August 2019 and October 2019 convertible notes, with $171,266 of principal and accrued interest past due. It was negotiating maturity extensions. Other notes carry variable-price conversion terms, default-rate interest and potential penalties.
- Dilution and financing: Convertible-note conversions and warrant exercises drove significant share issuance. The company reported 197,308,116 common shares reserved for future issuance under lender reserve requirements. It also reported 2,002,490 shares issuable at quarter-end, issued in October. A subsequent October financing added another convertible note.
- Research and development: PRP remained preclinical. Management described patent progress and research collaboration activity, but provided no clinical-trial start date or financial guidance. The filing gives differing patent portfolio counts in separate sections; verify the current totals.
- Other notable matters: A $30,000 IRS penalty, plus accrued interest, related to late historical information returns remained accrued while the company awaited an IRS response. The company reported no material pending or threatened litigation. COVID-19’s future effect on operations and financing remained uncertain.
- Controls: Management concluded disclosure controls were ineffective and reported continuing material weaknesses, including inadequate written procedures, insufficient segregation of duties, no audit committee and weak review of the financial-close process. Planned remediation is subject to raising sufficient capital.
- Related-party and equity items: The company issued shares in exchange for accrued compensation and services, including shares to the CEO, the CEO’s wife, a director and a consultant. These transactions, alongside variable-conversion debt and warrant exercises, are important to assess for dilution and governance implications.
Important facts for investors to verify
- Available cash, near-term cash burn, and the company’s financing runway and ability to meet obligations.
- Status of negotiations on the $171,266 of past-due note obligations and terms, defaults, and conversion prices of outstanding convertible debt.
- Fully diluted share count, including lender reserves, outstanding warrants, shares issuable, and subsequent-period issuances.
- Progress toward clinical development of PRP, required funding, and the status and consistent count of granted and pending patents.
- Whether management addresses the going-concern uncertainty and material weaknesses in internal controls.